The goals of this study were to determine whether combining DHA with Apo2L/TRAIL could promote synergistic antitumor activity and to understand the exact mechanism by which combination therapy using these agents elicits pancreatic cancer cell death in vitro and in vivo. Here, TNFSF10 is linked to familial pancreatic carcinoma.